Kathryn G Link1, Michael T Stobb2, Matthew G Sorrells3, Maria Bortot4, Katherine Ruegg5, Marilyn J Manco-Johnson5,6, Jorge A Di Paola5,6, Suzanne S Sindi2, Aaron L Fogelson1,7, Karin Leiderman8, Keith B Neeves4,5,6. 1. Department of Mathematics, University of Utah, Salt Lake City, UT, USA. 2. Department of Applied Mathematics, University of California Merced, Merced, CA, USA. 3. Department of Chemical and Biological Engineering, Colorado School of Mines, Golden, CO, USA. 4. Department of Bioengineering, University of Colorado, Aurora, CO, USA. 5. Hemophilia and Thrombosis Center, University of Colorado, Aurora, CO, USA. 6. Department of Pediatrics, University of Colorado, Aurora, CO, USA. 7. Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA. 8. Department of Applied Mathematics and Statistics, Colorado School of Mines, Golden, CO, USA.
Abstract
BACKGROUND: The variability in bleeding patterns among individuals with hemophilia A, who have similar factor VIII (FVIII) levels, is significant and the origins are unknown. OBJECTIVE: To use a previously validated mathematical model of flow-mediated coagulation as a screening tool to identify parameters that are most likely to enhance thrombin generation in the context of FVIII deficiency. METHODS: We performed a global sensitivity analysis (GSA) on our mathematical model to identify potential modifiers of thrombin generation. Candidates from the GSA were confirmed by calibrated automated thrombography (CAT) and flow assays on collagen-tissue factor (TF) surfaces at a shear rate of 100 per second. RESULTS: Simulations identified low-normal factor V (FV) (50%) as the strongest modifier, with additional thrombin enhancement when combined with high-normal prothrombin (150%). Low-normal FV levels or partial FV inhibition (60% activity) augmented thrombin generation in FVIII-inhibited or FVIII-deficient plasma in CAT. Partial FV inhibition (60%) boosted fibrin deposition in flow assays performed with whole blood from individuals with mild and moderate FVIII deficiencies. These effects were amplified by high-normal prothrombin levels in both experimental models. CONCLUSIONS: These results show that low-normal FV levels can enhance thrombin generation in hemophilia A. Further explorations with the mathematical model suggest a potential mechanism: lowering FV reduces competition between FV and FVIII for factor Xa (FXa) on activated platelet surfaces (APS), which enhances FVIII activation and rescues thrombin generation in FVIII-deficient blood.
BACKGROUND: The variability in bleeding patterns among individuals with hemophilia A, who have similar factor VIII (FVIII) levels, is significant and the origins are unknown. OBJECTIVE: To use a previously validated mathematical model of flow-mediated coagulation as a screening tool to identify parameters that are most likely to enhance thrombin generation in the context of FVIII deficiency. METHODS: We performed a global sensitivity analysis (GSA) on our mathematical model to identify potential modifiers of thrombin generation. Candidates from the GSA were confirmed by calibrated automated thrombography (CAT) and flow assays on collagen-tissue factor (TF) surfaces at a shear rate of 100 per second. RESULTS: Simulations identified low-normal factor V (FV) (50%) as the strongest modifier, with additional thrombin enhancement when combined with high-normal prothrombin (150%). Low-normal FV levels or partial FV inhibition (60% activity) augmented thrombin generation in FVIII-inhibited or FVIII-deficient plasma in CAT. Partial FV inhibition (60%) boosted fibrin deposition in flow assays performed with whole blood from individuals with mild and moderate FVIII deficiencies. These effects were amplified by high-normal prothrombin levels in both experimental models. CONCLUSIONS: These results show that low-normal FV levels can enhance thrombin generation in hemophilia A. Further explorations with the mathematical model suggest a potential mechanism: lowering FV reduces competition between FV and FVIII for factor Xa (FXa) on activated platelet surfaces (APS), which enhances FVIII activation and rescues thrombin generation in FVIII-deficient blood.
Authors: W C Nichols; K Amano; P M Cacheris; M S Figueiredo; K Michaelides; R Schwaab; L Hoyer; R J Kaufman; D Ginsburg Journal: Blood Date: 1996-08-15 Impact factor: 22.113
Authors: F Rodeghiero; A Tosetto; T Abshire; D M Arnold; B Coller; P James; C Neunert; D Lillicrap Journal: J Thromb Haemost Date: 2010-09 Impact factor: 5.824
Authors: Yesim Dargaud; Suzette Béguin; Anne Lienhart; Raed Al Dieri; Christine Trzeciak; Jean Claude Bordet; H Coenraad Hemker; Claude Negrier Journal: Thromb Haemost Date: 2005-03 Impact factor: 5.249
Authors: Kathryn G Link; Matthew G Sorrells; Nicholas A Danes; Keith B Neeves; Karin Leiderman; Aaron L Fogelson Journal: Multiscale Model Simul Date: 2020-11-18 Impact factor: 1.930
Authors: Kathryn G Link; Michael T Stobb; Dougald M Monroe; Aaron L Fogelson; Keith B Neeves; Suzanne S Sindi; Karin Leiderman Journal: Arterioscler Thromb Vasc Biol Date: 2020-10-29 Impact factor: 8.311
Authors: Robert Ariens; Cecilia Becattini; Markus Bender; Wolfgang Bergmeier; Elisabetta Castoldi; Katrien Devreese; Martin Ellis; David Gailani; Vera Ignjatovic; Paula D James; Steven Kerrigan; Michele Lambert; Lai Heng Lee; Marcel Levi; Norma Maugeri; Joost Meijers; Juan Melero-Martin; Alan D Michelson; Federico Mingozzi; Keith Neeves; Heyu Ni; Anna-Karin Olsson; Zoltán Prohászka; Marie Ranson; Nicoletta Riva; Yotis Senis; Cornelia H van Ommen; Douglas E Vaughan; John Weisel Journal: Res Pract Thromb Haemost Date: 2020-07-12
Authors: William J Wulftange; Erdem Kucukal; Yuncheng Man; Ran An; Karamoja Monchamp; Charlotte D Sevrain; Himanshu R Dashora; Amma T Owusu-Ansah; Allison Bode; Anton Ilich; Jane A Little; Nigel S Key; Umut A Gurkan Journal: Br J Haematol Date: 2022-07-13 Impact factor: 8.615